PR95195

BEIJING, March 28, 2022 /PRNewswire=KYODO JBN/ --

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as

"Biocytogen") announced the opening of the Biocytogen Europe Innovation Center

(BEIC) in Heidelberg, Germany.

Local government representatives, clinical experts, and colleagues and

collaborators from multi-national companies made speeches at the opening

ceremony. Dr. Vivian Tian, Head of BEIC, hosted the event, and introduced

Biocytogen's history, pipeline, and technology platforms, as well as the

strategic positioning of BEIC. The center's opening was also attended by local

and US pharmaceutical and biotechnology partners and colleagues, investigators

from research institutions, university hospitals, and other local biotechnology

professional organizations.

Germany has long been considered the "world's pharmacy" — home to Bayer, Merck

and Boehringer Ingelheim – with its strength most recently highlighted by the

success of the COVID-19 mRNA vaccine. In particular, Heidelberg is a scientific

hub in Germany with several renowned institutions, including the Germany Cancer

Research Center, the European Molecular Biology Laboratory, and four Max Planck

Institutes. This environment of innovation, world-class facilities and top

scientific talent positions the BEIC to form new collaborations with European

partners to develop and commercialize Biocytogen's clinical and preclinical

assets, as well as to further strengthen local partnerships to discover novel

antibody drugs emerging from Biocytogen's Project Integrum, a large-scale

initiative to develop antibodies with first-in-class and/or best-in-class

potential to over 1000 druggable targets.

"The opening of the Biocytogen Europe Innovation Center is a strategic and

momentous step forward in strengthening our global business, and it is a

welcome message to our peers here that we're looking forward to working

together with you to make innovative drugs that benefit patients around the

world," remarked Dr. Yuelei Shen, Chairman and CEO of Biocytogen.

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology

company that drives the research and development of novel antibody-based drugs.

Founded in 2009, the company is committed to becoming a global headstream of

new drugs to bring benefits to patients around the world. Using its proprietary

fully human antibody RenMabTM and RenLiteTM mice, Biocytogen has integrated its

monoclonal and bispecific antibody development platforms, in vivo drug efficacy

screening platforms and strong clinical development ability to streamline the

entire drug development process. Biocytogen is undertaking a large-scale

initiative to develop antibody drugs for more than 1000 potential druggable

targets, known as Project Integrum. With the implementation of Project

Integrum, Biocytogen has entered ongoing collaborations with dozens of partners

worldwide to produce first-in-class and/or best-in-class antibody drugs to

benefit patients. Currently, the company has established a pipeline of 12 core

products, with 2 products in phase II multi-regional clinical trials (MRCT) and

2 products in phase I trials. Headquartered in Beijing, Biocytogen has branches

in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.

SOURCE:  Biocytogen

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=417898